CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia With Gene Mutations; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia Interventions: Drug: Ivosidenib; Drug: Liposome-encapsulated Daunorubicin-Cytarabine Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Leukemia | Myelodysplastic Syndrome | Research